Home › Compare › SYNI vs EQR

SYNI vs EQR: Dividend Comparison 2026

SYNI yields 200000000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYNI wins by $4.875657285131069e+59M in total portfolio value
10 years
SYNI
SYNI
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full SYNI calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SYNI vs EQR

📍 SYNI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYNI + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SYNI pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYNI
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, SYNI beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYNI + EQR for your $10,000?

SYNI: 50%EQR: 50%
100% EQR50/50100% SYNI
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SYNI
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYNI buys
0
EQR buys
14
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002025-08-26
Ritchie Torres🏢 House$EQR▼ Sell$1,001 - $15,0002025-07-11
Dan Newhouse🏢 House$EQR▼ Sell$1,001 - $15,0002025-04-11
Ritchie Torres🏢 House$EQR▲ Buy$1,001 - $15,0002024-09-26
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002023-10-31
Daniel Goldman🏢 House$EQR▼ Sell$50,001 - $100,0002023-07-12
Dan Newhouse🏢 House$EQR▲ Buy$1,001 - $15,0002023-04-26
Ro Khanna🏢 House$EQR▲ Buy$1,001 - $15,0002023-03-24
Ro Khanna🏢 House$EQR▼ Sell$1,001 - $15,0002023-03-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNIEQR
Forward yield200000000.00% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4.875657285131069e+59M$47.8K ✓
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$5,475.61
Total dividends collected$4.875656971401711e+59M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SYNI vs EQR ($10,000, DRIP)

YearSYNI PortfolioSYNI Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$11,380$679.82+$20000.00M → SYNI
2$37,383,218,970,104,910$37,383,197,570,093,464.00$13,014$837.25+$37383218970.09M → SYNI
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$14,961$1,036.20+$65303942472059152.00M → SYNI
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$17,297$1,289.22+$1.0661500906030689e+23M → SYNI
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$20,121$1,613.15+$1.6267227396708296e+29M → SYNI
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$23,561$2,030.84+$2.319663403067553e+35M → SYNI
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$27,783$2,573.54+$3.091381823051466e+41M → SYNI
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$33,013$3,284.39+$3.850317772522584e+47M → SYNI
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$39,547$4,223.51+$4.481844117993459e+53M → SYNI
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$47,791$5,475.61+$4.875657285131069e+59M → SYNI

SYNI vs EQR: Complete Analysis 2026

SYNI — Stock

Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company's products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy. It is also developing a diagnostic test to identify and treat patients with diabetes who are in risk of cardiovascular disease. The company, formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Montvale, New Jersey.

Full SYNI Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SYNI vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYNI vs SCHDSYNI vs JEPISYNI vs OSYNI vs KOSYNI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.